130 related articles for article (PubMed ID: 1439155)
1. Clinical applications of IL6 inhibitors.
Klein B; Lu ZY; Bataille R
Res Immunol; 1992 Sep; 143(7):774-6. PubMed ID: 1439155
[No Abstract] [Full Text] [Related]
2. Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and soluble gp130.
Van Zaanen HC; Lokhorst HM; Aarden LA; Rensink HJ; Warnaar SO; Van Oers MH
Leuk Lymphoma; 1998 Nov; 31(5-6):551-8. PubMed ID: 9922045
[TBL] [Abstract][Full Text] [Related]
3. [Anti-cytokine therapy for intractable hematologic diseases using monoclonal antibodies].
Nishimoto N
Nihon Naika Gakkai Zasshi; 2004 Feb; 93(2):390-6. PubMed ID: 15007951
[No Abstract] [Full Text] [Related]
4. Interleukin-6, a new target for therapy in multiple myeloma?
van Oers MH; van Zaanen HC; Lokhorst HM
Ann Hematol; 1993 May; 66(5):219-23. PubMed ID: 8507716
[TBL] [Abstract][Full Text] [Related]
5. Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo.
Suzuki H; Yasukawa K; Saito T; Goitsuka R; Hasegawa A; Ohsugi Y; Taga T; Kishimoto T
Eur J Immunol; 1992 Aug; 22(8):1989-93. PubMed ID: 1639101
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting IL-6 in human multiple myeloma.
Klein B; Lu ZY; Gaillard JP; Harousseau JL; Bataille R
Curr Top Microbiol Immunol; 1992; 182():237-44. PubMed ID: 1490360
[No Abstract] [Full Text] [Related]
7. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth.
Sato K; Tsuchiya M; Saldanha J; Koishihara Y; Ohsugi Y; Kishimoto T; Bendig MM
Cancer Res; 1993 Feb; 53(4):851-6. PubMed ID: 8428365
[TBL] [Abstract][Full Text] [Related]
8. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop.
van Zaanen HC; Koopmans RP; Aarden LA; Rensink HJ; Stouthard JM; Warnaar SO; Lokhorst HM; van Oers MH
J Clin Invest; 1996 Sep; 98(6):1441-8. PubMed ID: 8823310
[TBL] [Abstract][Full Text] [Related]
9. Technology evaluation: MRA, Chugai.
Ding C; Jones G
Curr Opin Mol Ther; 2003 Feb; 5(1):64-9. PubMed ID: 12669473
[TBL] [Abstract][Full Text] [Related]
10. Acquisition of growth autonomy and tumorigenicity by an interleukin 6-dependent human myeloma cell line transfected with interleukin 6 cDNA.
Okuno Y; Takahashi T; Suzuki A; Fukumoto M; Nakamura K; Fukui H; Koishihara Y; Ohsugi Y; Imura H
Exp Hematol; 1992 May; 20(4):395-400. PubMed ID: 1568457
[TBL] [Abstract][Full Text] [Related]
11. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study.
van Zaanen HC; Lokhorst HM; Aarden LA; Rensink HJ; Warnaar SO; van der Lelie J; van Oers MH
Br J Haematol; 1998 Aug; 102(3):783-90. PubMed ID: 9722307
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of interleukin-6 during therapy with anti-interleukin-6 monoclonal antibodies: enhanced clearance of interleukin-6 by a combination of three anti-interleukin-6 antibodies.
Montero-Julian FA; Gautherot E; Wijdenes J; Klein B; Brailly H
J Interferon Res; 1994 Oct; 14(5):301-2. PubMed ID: 7861038
[No Abstract] [Full Text] [Related]
13. IL-6 as a growth factor for human multiple myeloma cells--a short overview.
Nilsson K; Jernberg H; Pettersson M
Curr Top Microbiol Immunol; 1990; 166():3-12. PubMed ID: 2073810
[No Abstract] [Full Text] [Related]
14. Gp130 in human myeloma/plasmacytoma.
Tani Y; Nishimoto N; Ogata A; Shima Y; Yoshizaki K; Kishimoto T
Curr Top Microbiol Immunol; 1995; 194():229-33. PubMed ID: 7895494
[No Abstract] [Full Text] [Related]
15. Mouse anti-human interleukin-6 receptor monoclonal antibody inhibits proliferation of fresh human myeloma cells in vitro.
Goto H; Shimazaki C; Tatsumi T; Yamagata N; Hirata T; Ashihara E; Oku N; Inaba T; Fujita N; Koishihara Y
Jpn J Cancer Res; 1994 Sep; 85(9):958-65. PubMed ID: 7961126
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives.
Lonial S; Durie B; Palumbo A; San-Miguel J
Leukemia; 2016 Mar; 30(3):526-35. PubMed ID: 26265184
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of interleukin (IL)-6 receptor gene expression in vitro and in vivo in IL-6 deprived myeloma cells.
Portier M; Lees D; Caron E; Jourdan M; Boiron JM; Bataille R; Klein B
FEBS Lett; 1992 May; 302(1):35-8. PubMed ID: 1587349
[TBL] [Abstract][Full Text] [Related]
18. Factors affecting the in vitro evolution of a myeloma cell line.
Scibienski RJ; Paglieroni T; Caggiano V; Lemongello D; Gumerlock PH; Mackenzie MR
Leukemia; 1992 Sep; 6(9):940-7. PubMed ID: 1518305
[TBL] [Abstract][Full Text] [Related]
19. [gp-130 related cytokines in mechanisms of myeloma cell growth].
Fukutoku M; Shimizu S
Rinsho Ketsueki; 1997 Apr; 38(4):262-5. PubMed ID: 9146047
[No Abstract] [Full Text] [Related]
20. Effects of all-trans retinoic acid and antireceptor antibodies on growth and programmed cell death of human myeloma cells.
Taetle R; Dos Santos B; Akamatsu K; Koishihara Y; Ohsugi Y
Clin Cancer Res; 1996 Feb; 2(2):253-9. PubMed ID: 9816167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
